KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenGrob kalibriertAktuelle implizite WahrscheinlichkeitBefore Jan 1, 2031 56%Führend unter 6 Optionen
Marktqualitat
37 / 100
Niedrige Qualität24h-Volumen
0 €
Liquidität
1310,8 €
Niedrige LiquiditätGeld / Brief
10.0% / 16.0%
Spread
6.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 23 Minuten
14. Mai 26, 2:001. Jan. 27, 4:59
Trends
Nur virtuelles Guthaben – kein echtes GeldKeine Finanzberatung
Gewähltes Ergebnis
Before Jan 1, 202710%
Volumentrend
$22. Juli10T Daten27. Juli
Verwandte Märkte
Will the FDA approve camizestrant for advanced breast cancer?
47 €Before Oct 1, 2026: 37%KALSHI
KALSHI
Hantavirus pandemic in 2026?
92.653,1 €Ja: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
7454,6 €26-27M: 88%POLYMARKET
POLYMARKET
New pandemic in 2026?
5073,7 €Ja: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
2438,7 €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2059,2 €Ja: 5%KALSHI
KALSHIIn diesen Themen aktiv
Regeln
If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: